Phase:Open Label, I
Principal Investigator(s):
Objective:A Phase 1 Open Label Safety and Pharmacokinetic Study of Single Dose Rectal Administration of an Elvitegravir Insert at Two Dose Levels   Last Updated May 3, 2021
Prevention Option(s):Microbicides, MPTs
Study Design:
Arms and Assigned Interventions
DescriptionTAF/EVG Insert (20/16 mg) administered rectally by study staff
Mode of DeliveryTablet
Official Code: NCT04047420
Trial Sponsors: MTN
Start Date
End Date
December 11, 2019
March 30, 2021
Age range: 18 Years ↔ any
Population:Cisgender Men, Cisgender Women